your market intelligence analyst
Search Results
Edit Save
118,869 results
The selections or defaults defined for this collection may have been too restrictive for this search query. You can refine your results for this search.
PubMed News (NIH) 10/27/2020
Contributors : Silvia Ardissone ; Nicolas Kint ; Bianca Petrignani ; Gaël Panis ; Patrick H Viollier Series Type : Expression profiling by high throughput sequencing Organism : Caulobacter vibrioides. How cellular checkpoints couple the orderly assembly of macromolecular machines with cell cycle progression is poorly understood.
PubMed News (NIH) 10/27/2020
Contributors : V Soumya ; Malini Laloraya Series Type : Expression profiling by array Organism : Mus musculus. Gene expression microarray data from Aire silenced pregnant uteri revealed 1465 transcripts which were differentially expressed. Pathway analysis based on the differentially expressed genes revealed immune pathway, spliceosome network, adhesion pathway, TGF pathway and WNT pathway. AIRE is previously known for its immune related role and its relation to splicing is reported. Adhesion, TGF pathway and WNT pathways were novel pathways that came up during pathway analysis.
PubMed News (NIH) 10/27/2020
Contributors : Siok-Bian Ng ; Shangying Chen Series Type : Expression profiling by array Organism : Homo sapiens. The molecular biology of the primary nodal EBV-positive variant of PTCL (PTCL-EBV) and its relationship with extranodal NK/T-cell lymphoma (ENKTL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) remains poorly understood.
GlobeNewswire 10/27/2020
VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Medicines & Healthcare product Regulatory Agency (MHRA) of the U.K. government has cleared CytoDyn to file its Biologics License Application (BLA) for leronlimab as a combination therapy for multi-drug resistance HIV patients in the U.K.
Election Law 10/26/2020 23:52
NYT: In August, The New York Post published an article that relied on one anonymous source, identified as a Democratic operative, who claimed that he had engaged in voter fraud for decades. The Blaze, Breitbart, Daily Caller, and The …
SurgRob 10/26/2020 23:48
Haidegger & Krieger Guest Editors. Manuscript Submission Information. Manuscripts should be submitted online at by and . Once you are registered, . Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All ma.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.